Press release
Natera Reports First Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.\n\nRecent Strategic and Financial Highlights\n\n\nGenerated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period.\n\n\nGenerated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024.\n\n\nProcessed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of 16.2%.\n\n\nPerformed approximately 167,700 oncology tests in the first quarter of 2025, compared to approximately 114,800 in the first quarter of 2024, an increase of 46.1%.\n\n\nAchieved positive cash flow of approximately $23.2 million1 in the first quarter of 2025.\n\n\n“We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera,” said Steve Chapman, chief executive officer of Natera. “Our progress reflects the strength of our technology and the breadth and quality of the clinical data. With multiple high-impact datasets reading out and trials underway, we believe we’re in a strong position to help millions of patients in the future.”\n\nFirst Quarter Ended March 31, 2025 Financial Results\n\nTotal revenues were $501.8 million in the first quarter of 2025 compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. The increase in total revenues was driven primarily by a 37.1% increase in product revenues, which were $500.0 million in the first quarter of 2025 compared to $364.7 million in the first quarter of 2024. The increase in product revenues was primarily driven by an increase in volume and average selling price improvements, as well as cash receipts that were collected during the quarter in excess of initial revenue estimates for tests delivered in prior quarters.\n\nNatera processed approximately 855,100 tests in the first quarter of 2025, including approximately 840,800 tests accessioned in its laboratory, compared to approximately 735,800 tests processed, including approximately 718,700 tests access...